A Phase 2 interventional study of Etavopivat in Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R, sponsored by Forma Therapeutics, Inc.. Terminated at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Forma Therapeutics, Inc. (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.
Among the 464 studies in Anemia with a site in United States, this one is the 306th largest by enrollment of the 395 interventional ones that give a count, is one of 13 that started in 2022, is one of 109 in phase 2, and was the 415th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
464 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 136 · Phase 3 122 · Phase 4 34
First in 1992; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 395 interventional studies, 116 across the 50 observational. Of the 367 that completed or were terminated, 196 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 464 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forma Therapeutics, Inc., one of the names counted as Novo Nordisk A/S. Under that name alone:
Forma Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Novo Nordisk A/S has 4 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
Add all 10 to your calendar (.ics) → With an account.
Among the 464 studies in Anemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented diagnosis of idiopathic/de novo MDS according to World Health Organization (WHO) classification that meets the IPSS-R classification of very low, low, or intermediate risk disease, and:
Anemia defined as:
OR
EXCLUSION CRITERIA:
[MDS History]
Known history of acute myeloid leukemia (AML)
[Medical Conditions]
Hepatic dysfunction characterized by:
Patients with clinically significant and active bacterial, fungal, parasitic, or viral infection.
Note: Infection prophylaxis is allowed.
History of , other than MDS, within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation.
History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable).
[Prior/Concomitant Therapy]
Prior use of luspatercept:
Initiation of a new chelation therapy within 3 months before the first dose of study treatment.
[Prior/Concurrent Clinical Study Experience]
Participated in another clinical trial of an agent (or medical device) within 30 days or 5 half-lives of date of , whichever is longer, or is currently participating in another trial of an investigational agent (or medical device).
[Other Exclusions]
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-transfusion dependent (NTD), Low transfusion burden (LTB) , and High transfusion burden (HTB) patients
Drug: Etavopivat
400 mg once daily
Also known as: FT-4202
Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment
This outcome measure reported on the combined incidence of NTD, LTB and HTB in terms of (HI-E) response for \>=8 weeks duration in participants with myelodysplastic syndromes (MDS) within 24 weeks. The participants were allocated to the following arms which were defined as: 1) NTD: \>=1.5 grams per deciliter (g/dL) increase in haemoglobin (Hb) from baseline maintained \>=8 consecutive weeks and no transfusion of RBC units for anemia over a continuous 8-week treatment period; 2) LTB: absence of any transfusion for \>=8 consecutive weeks; and 3) HTB: reduction by \>=50 percent (%) of RBC units for \>=8 consecutive weeks.
Time frame: From Baseline to Week 24
Percentage of Participants With Hematologic Improvement-Erythroid (HI-E) Response for =>8 Weeks Within 16 and 48 Weeks of Etavopivat
This outcome measure focused on the combined incidence of NTD, LTB and HTB participants, evaluating HI-E lasting =\>8 weeks in individuals with MDS within 16 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>8 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>8 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>8 consecutive weeks.
Time frame: 48 weeks
Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for =>16 Weeks Within 24 and 48 Weeks of Etavopivat
This outcome measure focused on the combined incidence of NDT, LTB and HTB participants, evaluating HI-E response lasting =\>16 weeks in individuals with MDS within 24 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>16 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>16 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>16 consecutive weeks.
Time frame: 48 weeks
Number of All Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Related to Etavopivat
This outcome measures the total number of AEs and SAEs in participants, including AEs related to etavopivat. AEs are any unfavorable medical occurrences in participants taking the medicinal product, regardless of causality. They include new or worsening symptoms, abnormal lab findings, and exacerbations of existing conditions, documented from the first dose through 28 days after the last dose. SAEs are severe AEs that result in death, are life-threatening, require hospitalization, lead to significant disability, or involve congenital anomalies. Important medical events posing risks to the participants are also classified as SAEs. Treatment Emergent Adverse Events (TEAEs) are AEs occurring after treatment initiation, aiding in the safety assessment of etavopivat. TEAEs will be considered drug-related if assessed by the Investigator as possibly related or related, or if relationship is missing.
Time frame: From baseline up to 48 weeks
Number of Premature Discontinuations, Dose Interruptions, and Dose Reductions
The outcome measures the total number of premature discontinuations, dose interruptions and dose reductions. Premature discontinuation was defined as any discontinuation prior to week 48. A dose interruption is a temporary halt in treatment due to an AE, while a dose reduction involves lowering the dosage of the drug when AEs occur. If a participant tolerates a reduced dose for 14 days, a rechallenge with the original dose may occur after a clinic visit, but any new Grade 3 or higher AEs require treatment discontinuation and consultation with the Global Medical Monitor before resuming.
Time frame: Within 48 weeks
Overall Response Rate
The Overall Response Rate (ORR) is defined as the percentage of participants who achieve a predefined level of response according to the 2006 International Working Group (IWG) criteria, assessed at each scheduled evaluation.
Time frame: Up to 48 weeks
Duration of Response
This outcome measure reported duration of response which was defined as duration of response will be summarized with quantiles based on product limit estimates (ie, Kaplan-Meier). Duration of response is defined as the time from date of first known incidence of a 2006 IWG criteria response to the most recent date that the 2006 IWG (International Working Group) criteria is not met following the initial response. If the participant has met IWG criteria throughout the period following the initial response, the participant will be censored at the latest date of end of study, loss to follow-up, or death.
Time frame: Up to 48 weeks
Reduction in RBC Transfusions for >=8 Weeks in Participants With LTB or HTB at Study Entry
This outcome measure reports reduction in RBC transfusion by 8-week interval in participants with LTB and HTB.
Time frame: Up to 48 weeks
Percent Change From Baseline in RBC Transfusion Independence for =>8 Weeks in Participants With LTB or HTB at Study Entry
This outcome measure is percent change in RBC transfusion by 8-week interval in participants with LTB and HTB. Percent reduction from baseline in RBC transfusion burden is defined as -100×(Total RBC Units Transfused During Interval)/(Baseline RBC Units Transfused Per 8 Weeks).
Time frame: Up to 48 weeks
Change From Baseline in Neutrophils and/or Platelets Counts
This outcome measure reports the change from baseline in neutrophils and/or platelets counts from baseline to week 48
Time frame: Baseline (week 0), week 48
Decrease in Ferritin and Transferrin Saturation (TSAT)
This outcome measure were to report decrease in ferritin and TSAT from baseline to Week 48.
Time frame: Up to 48 weeks
Decrease in Iron Chelation Therapy
This outcome measure were to report decrease of Iron chelation therapy and will be recorded at Screening and on an ongoing basis throughout the study.
Time frame: up to 48 weeks
Overall Survival
Overall survival is defined as the time from first dose to date of death. If the participant was alive at last contact, the end date will be censored at the latest of either end of study, loss to follow-up, or study discontinuation.
Time frame: Within 48 weeks
Etavopivat Plasma Concentrations
This outcome measure reported Etavopivat plasma concentrations in order to assess the PK properties of etavopivat in participants with MDS. PK parameters included but not limited to were: Time to maximum observed plasma concentration, area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last), from time zero to infinity (AUC0-inf), for a dosing interval (AUCtau/AUC0-24).) However due to early termination of the study, the PK parameters were not assessed and only the plasma concentrations could be assessed.
Time frame: Weeks 1 and 4 pre-dose, post-dose 1, 2, 4, 6 hours.Week 2 and EOT (week 48):pre-dose, post-dose 1, 2 hours
RBC 2,3-diphosphoglycerate (2,3-DPG) and Adenosine Triphosphate (ATP) Levels Over Time
Etavopivat plasma concentrations were collected in order to assess the pharmacodynamic (PD) properties of etavopivat in participants with MDS.
Time frame: Within 48 weeks
The trial was conducted at 10 sites in 4 countries.
| Milestone | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Started | 3 | 5 | 9 |
| Efficacy evaluable set (ees) | 1 | 2 | 4 |
| Safety population | 3 | 5 | 9 |
| Full analysis set (fas) | 3 | 5 | 9 |
| Pharmacokinetic (pk) set | 3 | 5 | 9 |
| Completed | 1 | 2 | 4 |
| Not completed | 2 | 3 | 5 |
| Withdrew: Termination of the study by the sponsor | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal of conset | 1 | 0 | 4 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Milestone | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Started | 1 | 2 | 4 |
| Completed | 1 | 2 | 1 |
| Not completed | 0 | 0 | 3 |
| Withdrew: Termination of the study by the sponsor | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
This outcome measure reported on the combined incidence of NTD, LTB and HTB in terms of (HI-E) response for \>=8 weeks duration in participants with myelodysplastic syndromes (MDS) within 24 weeks. The participants were allocated to the following arms which were defined as: 1) NTD: \>=1.5 grams per deciliter (g/dL) increase in haemoglobin (Hb) from baseline maintained \>=8 consecutive weeks and no transfusion of RBC units for anemia over a continuous 8-week treatment period; 2) LTB: absence of any transfusion for \>=8 consecutive weeks; and 3) HTB: reduction by \>=50 percent (%) of RBC units for \>=8 consecutive weeks.
| Percentage of participants | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment | 0 | 50 | 25 |
This outcome measure focused on the combined incidence of NTD, LTB and HTB participants, evaluating HI-E lasting =\>8 weeks in individuals with MDS within 16 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>8 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>8 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>8 consecutive weeks.
No measurements were reported for this outcome.
This outcome measure focused on the combined incidence of NDT, LTB and HTB participants, evaluating HI-E response lasting =\>16 weeks in individuals with MDS within 24 weeks and 48 weeks. Participant's response were defined as follows: 1) NTD: an increase of =\>1.5 g/dL in Hb maintained for =\>16 consecutive weeks without any RBC transfusions for anemia; 2) LTB: no transfusions over =\>16 consecutive weeks; and 3) HTB: a reduction of =\>50% in RBC units for =\>16 consecutive weeks.
No measurements were reported for this outcome.
This outcome measures the total number of AEs and SAEs in participants, including AEs related to etavopivat. AEs are any unfavorable medical occurrences in participants taking the medicinal product, regardless of causality. They include new or worsening symptoms, abnormal lab findings, and exacerbations of existing conditions, documented from the first dose through 28 days after the last dose. SAEs are severe AEs that result in death, are life-threatening, require hospitalization, lead to significant disability, or involve congenital anomalies. Important medical events posing risks to the participants are also classified as SAEs. Treatment Emergent Adverse Events (TEAEs) are AEs occurring after treatment initiation, aiding in the safety assessment of etavopivat. TEAEs will be considered drug-related if assessed by the Investigator as possibly related or related, or if relationship is missing.
| Events | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| AE | 33 | 33 | 54 |
| SAE | 1 | 0 | 6 |
| AEs related to etavopivat | 0 | 0 | 1 |
| AEs possibly related etavopivat | 8 | 3 | 6 |
The outcome measures the total number of premature discontinuations, dose interruptions and dose reductions. Premature discontinuation was defined as any discontinuation prior to week 48. A dose interruption is a temporary halt in treatment due to an AE, while a dose reduction involves lowering the dosage of the drug when AEs occur. If a participant tolerates a reduced dose for 14 days, a rechallenge with the original dose may occur after a clinic visit, but any new Grade 3 or higher AEs require treatment discontinuation and consultation with the Global Medical Monitor before resuming.
| Events | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Premature discontinuations | 1 | 0 | 0 |
| Dose interruptions | 0 | 0 | 2 |
| Dose reductions | 0 | 0 | 0 |
The Overall Response Rate (ORR) is defined as the percentage of participants who achieve a predefined level of response according to the 2006 International Working Group (IWG) criteria, assessed at each scheduled evaluation.
No measurements were reported for this outcome.
This outcome measure reported duration of response which was defined as duration of response will be summarized with quantiles based on product limit estimates (ie, Kaplan-Meier). Duration of response is defined as the time from date of first known incidence of a 2006 IWG criteria response to the most recent date that the 2006 IWG (International Working Group) criteria is not met following the initial response. If the participant has met IWG criteria throughout the period following the initial response, the participant will be censored at the latest date of end of study, loss to follow-up, or death.
No measurements were reported for this outcome.
This outcome measure reports reduction in RBC transfusion by 8-week interval in participants with LTB and HTB.
| Total RBS units | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|
| Week 1-8 | 3.0 ± 2.83 | 5.8 ± 2.63 |
| Week 9-16 | 2.5 ± 2.12 | 6.3 ± 1.71 |
| Week 17-24 | 3.5 ± 2.12 | 7.5 ± 3.00 |
| Week 25-32 | 5.5 ± 0.71 | 7.3 ± 1.15 |
| Week 33-40 | 5.0 ± 4.24 | 6.7 ± 1.15 |
| Week 41-48 | 4.5 ± 2.12 | 7.5 ± 2.12 |
This outcome measure is percent change in RBC transfusion by 8-week interval in participants with LTB and HTB. Percent reduction from baseline in RBC transfusion burden is defined as -100×(Total RBC Units Transfused During Interval)/(Baseline RBC Units Transfused Per 8 Weeks).
| Percent change of total RBC units | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|
| Week 1-8 | -20.83 ± 64.818 | 68.75 ± 156.994 |
| Week 9-16 | -33.33 ± 47.140 | 68.75 ± 98.219 |
| Week 17-24 | -4.17 ± 41.248 | 120.83 ± 191.183 |
| Week 25-32 | 58.33 ± 11.785 | 127.78 ± 149.381 |
| Week 33-40 | 33.33 ± 94.281 | 94.44 ± 91.793 |
| Week 41-48 | 25.00 ± 35.355 | 50.00 ± 0 |
This outcome measure reports the change from baseline in neutrophils and/or platelets counts from baseline to week 48
| 10^9 cells per liter | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Neutrophils | -3.200 ± NA | -0.950 ± 0.0707 | -0.100 ± NA |
| Platelets counts | 43.0 ± NA | -51.0 ± 205.06 | -8.0 ± NA |
This outcome measure were to report decrease in ferritin and TSAT from baseline to Week 48.
No measurements were reported for this outcome.
This outcome measure were to report decrease of Iron chelation therapy and will be recorded at Screening and on an ongoing basis throughout the study.
No measurements were reported for this outcome.
Overall survival is defined as the time from first dose to date of death. If the participant was alive at last contact, the end date will be censored at the latest of either end of study, loss to follow-up, or study discontinuation.
No measurements were reported for this outcome.
This outcome measure reported Etavopivat plasma concentrations in order to assess the PK properties of etavopivat in participants with MDS. PK parameters included but not limited to were: Time to maximum observed plasma concentration, area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last), from time zero to infinity (AUC0-inf), for a dosing interval (AUCtau/AUC0-24).) However due to early termination of the study, the PK parameters were not assessed and only the plasma concentrations could be assessed.
| ng/mL | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Week 1 predose | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Week 1 post-dose 1 hour | 379.77 ± 292.748 | 904.80 ± 521.000 | 1016.78 ± 794.503 |
| Week 1 post-dose 2 hour | 751.67 ± 393.465 | 579.60 ± 403.593 | 519.11 ± 273.776 |
| Week 1 post-dose 4 hour | 274.50 ± 86.974 | 203.80 ± 134.884 | 165.16 ± 64.895 |
| Week 1 post-dose 6 hour | 63.50 ± NA | 101.02 ± 67.693 | 83.74 ± 40.170 |
| Week 2 pre-dose | 27.20 ± 17.843 | 19.08 ± 9.037 | 19.20 ± 12.240 |
| Week 2 post-dose 1 hour | 1156.00 ± 371.198 | 899.40 ± 442.555 | 1076.44 ± 693.907 |
| Week 2 post-dose 2 hour | 927.00 ± 310.140 | 1024.00 ± 530.102 | 661.78 ± 392.238 |
| Week 4 predose | 17.04 ± 11.540 | 24.34 ± 23.333 | 20.26 ± 9.289 |
| Week 4 post-dose 1 hour | 1050.00 ± 28.284 | 386.90 ± 214.249 | 913.20 ± 1013.207 |
| Week 4 post-dose 2 hour | 526.00 ± 134.350 | 453.40 ± 179.140 | 678.49 ± 379.918 |
| Week 4 post-dose 4 hour | 151.50 ± 12.021 | 383.73 ± 261.103 | 297.90 ± 282.646 |
| Week 4 post-dose 6 hour | 60.75 ± 11.526 | 148.13 ± 113.650 | 121.34 ± 115.306 |
| End of treatment pre-dose | — | 21.60 ± 5.798 | 24.20 ± NA |
| End of treatment post-dose 1 hours | — | 1620.00 ± NA | 1680.00 ± NA |
| End of treatment post-dose 2 hours | — | 571.00 ± NA | 815.00 ± NA |
Etavopivat plasma concentrations were collected in order to assess the pharmacodynamic (PD) properties of etavopivat in participants with MDS.
No measurements were reported for this outcome.
Collected over Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-transfusion Dependent | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Low Transfusion Burden | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| High Transfusion Burden | 0/9 (0%) | 3/9 (33.3%) | 8/9 (88.9%) |
| Event | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| Cardiac failureCardiac disorders | 1/3 | 0/5 | 0/9 |
| Angina pectorisCardiac disorders | 0/3 | 0/5 | 1/9 |
| Arterial ruptureVascular disorders | 0/3 | 0/5 | 1/9 |
| Hip fractureInjury, poisoning and procedural complications | 0/3 | 0/5 | 1/9 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/3 | 0/5 | 1/9 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/3 | 0/5 | 1/9 |
| Staphylococcal infectionInfections and infestations | 0/3 | 0/5 | 1/9 |
| Event | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden |
|---|---|---|---|
| AnxietyPsychiatric disorders | 2/3 | 1/5 | 0/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/3 | 0/5 | 1/9 |
| Lymphocyte count decreasedInvestigations | 2/3 | 0/5 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/3 | 0/5 | 0/9 |
| PneumoniaInfections and infestations | 0/3 | 2/5 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/5 | 0/9 |
| Atrioventricular block second degreeCardiac disorders | 1/3 | 0/5 | 0/9 |
| Cardiac failureCardiac disorders | 1/3 | 1/5 | 0/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 0/5 | 1/9 |
| FatigueGeneral disorders | 1/3 | 0/5 | 1/9 |
FAS included all participants who signed the informed consent and received at least 1 dose of etavopivat.
| Age, Continuous(Years) | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden | Total |
|---|---|---|---|---|
| Mean | 77.3 ± 5.69 | 80.2 ± 3.49 | 71.2 ± 8.11 | 74.9 ± 7.58 |
| Sex: Female, Male(Participants) | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 3 | 4 |
| Male | 3 | 4 | 6 | 13 |
| Race/Ethnicity, Customized(Participants) | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden | Total |
|---|---|---|---|---|
| Race: White | 3 | 4 | 7 | 14 |
| Race: Not reported | 0 | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Non-transfusion Dependent | Low Transfusion Burden | High Transfusion Burden | Total |
|---|---|---|---|---|
| Ethnicity: Not Hispanic or Latino | 3 | 4 | 6 | 13 |
| Ethnicity: Hispanic or Latino | 0 | 1 | 1 | 2 |
| Ethnicity: Not Reported | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2022 to primary completion in Jul 2024, 20 months.
Results were first posted in Oct 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etavopivat